Michael C. Milone, MD, PhD
Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Associate Director, Toxicology Laboratory
University of Pennsylvania Perelman School of Medicine
Contact Information3400 Spruce Street 7103 Founders Pavilion
Philadelphia, PA 19104
Office: 215-662-6575
Fax: 215-662-7529
Email: milone@pennmedicine.upenn.edu
Specialty Division
Laboratory Medicine, Immunobiology and Experimental Pathology
Research Expertise
Research in my laboratory is focused on T cell biology and applications of genetically-engineered T cells to the treatment of disease. Active research projects in my laboratory include:
1) Developing chimeric antigen receptors (CARs) for adoptive immunotherapy of cancer with enhanced function and improved safety.
2) Developing and applying synthetic immunoreceptors to the treatment of immune-mediated disease.
3) Exploring the role of co-stimulatory signals in directing T cell metabolism and the way this metabolism affects T cell function within tumors.
Clinical Expertise
Clinical Laboratory Toxicology, Therapeutic Drug Monitoring, Clinical Chemistry, Blood Banking/Transfusion Medicine, Therapeutic Apheresis
Itmat Expertise
My laboratory is focused upon developing methods to use the immune system to treat cancer. Active research includes 1) exploring the mechanical properties of artificial adhesion substrates used in T cell culture and their influence on T cell biology, 2) development of artificial antigen receptors and signaling systems for control of T cell specificity
Graduate Groups
Cell and Molecular Biology
Education
B.S (Chemical Biology), Stevens Institute of Technology, 1993
Ph.D (Experimental Pathology/ Immunology), UMDNJ - Graduate School of Biomedical Sciences, 1999
M.D. (Medical Doctor), UMDNJ- New Jersey Medical School, 1999
Specialty Certification
Clinical Pathology, American Board of Pathology, 2002
Postgraduate Training
Internship, Internal Medicine, Hospital of the University of Pennsylvania, 1999-2000
Resident, Clinical Pathology, Hospital of the University of Pennsylvania, 2000-2002
Chief Resident, Division of Laboratory Medicine, Hospital of the University of Pennsylvania, 2001-2002
Clinical Fellowship, Blood Banking and Transfusion Medicine, Hospital of the University of Pennsylvania, 2002-2003
Postdoctoral. Research Fellow, Translational Research Program, Abramson Family Cancer Institute, University of Pennsylvania School of Medicine, 2003-2007
Clinical Fellow, Clinical Chemistry and Laboratory Toxicology, Hospital of the University of Pennsylvania, 2004-2007
Awards and Honors
Stanley S. Bergen Award for Academic Excellence, UMDNJ, 1996
Faculty Organization Award, UMDNJ-New Jersey Medical School, 1999
Stanely S. Bergen Medal of Excellence, UMDNJ, 1999
The Peter C. Nowell Teaching Award, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 2011
Top Ten Clinical Research Achievement Award, Clinical Research Forum, 2017
Memberships and Professional Organizations
American Association of Clinical Chemistry, 2007 - Present
American Society of Clinical Pharmacology and Therapeutics, 2007 - 2010
College of American Pathologists, 2008 - Present
Academy of Clinical Laboratory Physicians and Scientists, 2008 - 2015
American Society of Hematology, 2008 - Present
International Association of Therapeutic Drug Monitoring and Clinical Toxicology, 2009 - Present
American Association of Immunologists, 2009 - Present
American Society of Gene and Cell Therapy, 2009 - Present
American Society of Clinical Pathology, 2015 - Present
National Institute for innovation in Manufacturing Biopharmaceuticals (NIIMBL), 2017 - Present
Web Links
Selected Publications
An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.
Feins Steven, Kong Weimin, Williams Erik F, Milone Michael C, Fraietta Joseph A, American journal of hematology 94(S1): S3-S9, 2019, PMID:30680780
Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
Thibodeaux Suzanne R, Milone Michael C, Clinical chemistry 65(4): 519-529, 2019, PMID:30593467
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen Adam D, Garfall Alfred L, Stadtmauer Edward A, Melenhorst J Joseph, Lacey Simon F, Lancaster Eric, Vogl Dan T, Weiss Brendan M, Dengel Karen, Nelson Annemarie, Plesa Gabriela, Chen Fang, Davis Megan M, Hwang Wei-Ting, Young Regina M, Brogdon Jennifer L, Isaacs Randi, Pruteanu-Malinici Iulian, Siegel Don L, Levine Bruce L, June Carl H, Milone Michael C, The Journal of clinical investigation 130(): 2210-2221, 2019, PMID:30896447
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH., JCI Insight 4(4): pii: 127684, 2019, PMID:30830874
Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells.
Ghassemi Saba, Nunez-Cruz Selene, O'Connor Roddy S, Fraietta Joseph A, Patel Prachi R, Scholler John, Barrett David M, Lundh Stefan M, Davis Megan M, Bedoya Felipe, Leferovich John, Lacey Simon F, Levine Bruce L, Grupp Stephan A, June Carl H, Melenhorst J Joseph, Milone Michael C, Cancer immunology research, 2018, PMID:30030295
Clinical use of lentiviral vectors.
Milone Michael C, O'Doherty Una, Leukemia 32(7): 1529-1541, 2018, PMID:29654266
False-positive results following lentiviral-based tisagenlecleucel therapy with select HIV-1 NAT methods.
Laetsch Theodore W, Maude Shannon L, Milone Michael C, Davis Kara L, Krueger Joerg, Cardenas Ana Maria, Eldjerou Lamis K, Keir Christopher H, Wood Patricia A, Grupp Stephan A, Blood 131(23): 2596-2598, 2018, PMID:29669777
Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
De-xiu Bu, Reshma Singh, Eugene E. Choi,*, Marco Ruella, Selene Nunez- Cruz, Keith G. Mansfi eld, Paul Bennett, Nathanial Barton, Qilong Wu, Jiquan Zhang, Yongqiang Wang, Lai Wei, Shawn Cogan, Tucker Ezell, Shree Joshi, Kellie J. Latimer, Brian Granda, William R. Tschantz, Regina M. Young, Heather A. Huet, Celeste J. Richardson and Michael C. Milone, Oncotarget 9(40): 25764-25780, 2018, PMID:29899820
The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations.
O'Connor Roddy S, Guo Lili, Ghassemi Saba, Snyder Nathaniel W, Worth Andrew J, Weng Liwei, Kam Yoonseok, Philipson Benjamin, Trefely Sophie, Nunez-Cruz Selene, Blair Ian A, June Carl H, Milone Michael C, Scientific reports 8(1): 6289, 2018, PMID:29674640
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall Alfred L, Stadtmauer Edward A, Hwang Wei-Ting, Lacey Simon F, Melenhorst Jan Joseph, Krevvata Maria, Carroll Martin P, Matsui William H, Wang Qiuju, Dhodapkar Madhav V, Dhodapkar Kavita, Das Rituparna, Vogl Dan T, Weiss Brendan M, Cohen Adam D, Mangan Patricia A, Ayers Emily C, Nunez-Cruz Selene, Kulikovskaya Irina, Davis Megan M, Lamontagne Anne, Dengel Karen, Kerr Naseem Ds, Young Regina M, Siegel Donald L, Levine Bruce L, Milone Michael C, Maus Marcela V, June Carl H, JCI insight 3(8): , 2018, PMID:29669947
